Abstract: Prior to initiation of ART, ten percent, 3 of 29 isolates sequenced, had drug resistance mutations rtV173L, rtL180M+rtM204V and rtV214A, respectively.
Result: Three isolates had drug resistant mutations: SHH011 had rtV214A, SHH074 had rtL180M+rtM204V and SHH130 had rtV173L.
Discussion: Even though the participants in the present study had not initiated ART, ten percent, 3 of 29 isolates sequenced, had drug resis
Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Method: In addition to signature mutations, rtV173L, rtL180M and rtA181T/S were included in drug-resistant mutational patterns when they were present with signature resistance mutations.
Result: Of LAM-resistant mutations, rtM204V was usually concomitant with rtL180M +- V173L.
Result: Of the resistance mutations detected in patients who received monotherapies, rtM204I (32.2%), rtM204V + L180M +-
HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
Abstract: Drug-resistant mutations in the HBV polymerase were found in four (5.5%) patients: two harboured rtL180M, one rtL80V and one rtV173L.
Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
Abstract: LMV compensatory mutations rtL80V and rtV173L were seen in two and one patients, respectively.
Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations.
Discussion: Additional mutations able to restore replicative fitness to similar levels in the wild type such as rtV173L and rtP177S were not found.
Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
PMID: 21784687
2011
International journal of infectious diseases
Abstract: RESULTS: Seven types of ADAPVEM were detected in the total CHB patients: rtM204V/sI195M, rtM204I/sW196S, rtM204I/sW196L, rtV173L/sE164D, rtA181T/sW172*, rtA181T/
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.
Abstract: rtL80I/V-rtL180M-rtV173L), whilst most primary mutations (including rtM204V-rtA181T/V-rtI169T-rtA194T) are associated with low genetic barrier.
The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Abstract: HBV reverse-transcriptase (RT) region was sequenced and analyzed for 20 mutations, confirmed by in vitro studies as associated with resistance to nucleos(t)ide HBV-RT inhibitors (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C/G/I-
HBV mutation literature information.
PMID: 
2012
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT